Advertisement

Related Videos

Welcome and Introduction to Vi3C

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Varsha Gandhi, PhD, on Ibrutinib

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Advertisement

Advertisement




Aug
18
Today In Oncology
Overall Survival With Ivonescimab or Tislelizumab Plus Chemotherapy in Advanced Squamous NSCLC
Proton Pump Inhibitor, Antibiotic Exposure Linked to Inferior Durvalumab Outcomes in Unresectable Stage III NSCLC
Rezatapopt Shows Activity in TP53 Y220C–Mutated Advanced Ovarian Cancer
Sugar- vs Artificially Sweetened Beverages and Gastric Cancer Risk
High-Risk ERBB2-Negative Breast Cancer Adding Dual Checkpoint Blockade to Neoadjuvant Chemotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo